Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquisition |
multiple biotech firms
|
| gptkbp:advertising |
Mr. Kenji Takeda
Dr. Akira Yamamoto |
| gptkbp:annual_report |
published yearly
|
| gptkbp:awards |
various industry awards
|
| gptkbp:ceo |
Isao Teshirogi
|
| gptkbp:clinical_trial |
collaborative studies
published in peer-reviewed journals for COVID-19 treatments ongoing for various drugs |
| gptkbp:collaborations |
with biotech startups
|
| gptkbp:community_engagement |
local health programs
|
| gptkbp:competitors |
gptkb:Astra_Zeneca
gptkb:Pfizer gptkb:Merck_&_Co. gptkb:Novartis |
| gptkbp:conducts_research_on |
Dr. Yoshihiro Matsumoto
|
| gptkbp:employees |
approximately 5,000
|
| gptkbp:founded |
1878
|
| gptkbp:founder |
Taikichiro Shiono
|
| gptkbp:global_presence |
operates in over 20 countries
|
| gptkbp:governance |
adheres to best practices.
|
| gptkbp:headquarters |
gptkb:Osaka,_Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Shionogi & Co.
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:innovation |
focus on drug discovery
|
| gptkbp:invention |
numerous pharmaceutical patents
|
| gptkbp:investment |
provides updates to shareholders
in R& D |
| gptkbp:leadership |
diverse executive team
|
| gptkbp:market |
global pharmaceutical market
|
| gptkbp:partnership |
with various universities
with the World Health Organization with the Bill & Melinda Gates Foundation |
| gptkbp:partnerships |
various global pharmaceutical companies
|
| gptkbp:philanthropy |
supports health education initiatives
|
| gptkbp:products |
antibiotics
antiviral drugs pain management medications |
| gptkbp:research_areas |
oncology
cardiovascular diseases metabolic diseases |
| gptkbp:research_focus |
central nervous system disorders
infectious diseases pain management |
| gptkbp:revenue |
$1.5 billion (2020)
|
| gptkbp:social_responsibility |
healthcare access initiatives
|
| gptkbp:stock_exchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:stock_symbol |
4507
|
| gptkbp:strategy |
expansion into emerging markets
|
| gptkbp:subsidiaries |
Shionogi Pharma, Inc.
|
| gptkbp:sustainability_efforts |
environmental initiatives
|
| gptkbp:website |
www.shionogi.com
|
| gptkbp:bfsParent |
gptkb:Xofluza
|
| gptkbp:bfsLayer |
6
|